RETRACTED: Exploring the applications of formulation-based drug development strategies in neurological disorders using artificial intelligence and machine learning approaches

16 July 2024, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

The study of artificial intelligence (AI), a multidimensional field, empowers machines with the ability to understand, reason, learn, and perform tasks autonomously. As a pivotal branch of computer science, AI excels in analyzing complex medical data and uncovering significant relationships for diverse diagnostic purposes. In neurology, innovative AI techniques have revolutionized diagnostics, management, and outcome prediction, opening new avenues for tackling neurological disorders. AI encompasses two key subsets: machine learning (ML) and deep learning (DL), which have gained immense popularity for predicting bioactivity, toxicology, physical and chemical properties, formulation quality, and drug-target interactions. The complexity of neurological diseases (ND) presents unique challenges in developing treatments for the central nervous system (CNS), given obstacles like the blood-brain barrier and high medication attrition rates. However, AI algorithms, leveraging vast datasets, efficiently analyze, interpret, and predict unknown facts, significantly accelerating CNS drug discovery. Deep learning architectures have furthered our understanding of AI's potential to address complex CNS disease issues, transforming the drug development landscape. This review delves into AI, ML, and their applications in advancing CNS drug and formulation development. It provides comprehensive, up-to-date insights on AI/ML advancements in neurology, emphasizing nanoparticle-based drug delivery systems. Additionally, the review covers ML algorithms' roles in de novo drug design, structure-based drug design, ligand-based drug design, absorption, distribution, metabolism, excretion, and toxicity (ADMET) prediction, and drug repurposing. Despite notable progress, significant challenges remain in enhancing AI's practical application in neurology. Overcoming these hurdles requires compiling extensive data and developing interpretable AI systems, paving the way for groundbreaking advancements in CNS drug development.

Keywords

Artificial intelligence
Machine learning
Deep learning
Drug discovery
Formulation development
CNS diseases

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.